Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2191 to 2205 of 8215 results

  1. Eneboparatide for treating chronic hypoparathyroidism [TSID12145]

    Awaiting development Reference number: GID-TA11713 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]

    Awaiting development Reference number: GID-TA11111 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Imbio CT lung texture analysis for identifying interstitial lung disease (MT618) (MIB272)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  4. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]

    Awaiting development Reference number: GID-TA11383 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor TSID 11812

    Topic prioritisation

    Health technology evaluations
    Topic prioritisation

  6. Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

    Awaiting development Reference number: GID-TA10486 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Awaiting development Reference number: GID-TA11494 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Liposomal bupivacaine for treating postoperative pain [ID3799]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]

    Awaiting development Reference number: GID-TA11326 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development Reference number: GID-TA11161 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Cor-Knot for tying suture knots in valve surgery

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  12. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  13. Cytokine adsorption technologies for treating respiratory failure in people with COVID-19

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  14. Archimedes for biopsy of suspected lung cancer

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  15. Actim Pancreatitis for diagnosing acute pancreatitis

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation